Welcome to our dedicated page for Oramed Pharmaceuticals SEC filings (Ticker: ORMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oramed Pharmaceuticals Inc. reports material events and financial information through SEC filings that document its oral drug delivery business, investment-related agreements, and capital actions. Recent 8-K disclosures cover operating and financial results, option and warrant-related arrangements, payments tied to strategic investments, cash dividends, and material definitive agreements involving company assets and subsidiaries.
The filings also document Oramed’s common stock registration on the Nasdaq Capital Market and Tel Aviv Stock Exchange, its shareholder rights agreement, board-authorized distributions, and other capital-structure and governance matters. These records connect the company’s clinical-stage POD technology platform and oral insulin program with formal disclosures on liquidity, securities, contractual rights, and corporate events.
Oramed Pharmaceuticals reported net income of $38.3M for the three months ended March 31, 2026, compared with a net loss of $7.6M a year earlier. Basic EPS was $0.94.
Operating loss narrowed to $3.7M as research and development and general and administrative expenses declined. The swing to profitability was driven mainly by $44.8M of net financial income, including large fair value gains on investments such as Alpha Tau and Scilex, plus $8.3M of other income from a POD technology IP sale and recognizing $2.0M under the Medicox license.
Cash and cash equivalents fell to $13.2M from $45.9M at year-end 2025, while total assets increased to $268.8M as investment balances grew. The company completed the Lifeward transaction, transferring its POD technology into OraTech and receiving Lifeward shares, warrants and a convertible note, and it expanded its portfolio of structured investments and real estate–backed loans.
Oramed Pharmaceuticals Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The company states it requires additional time to complete and finalize the financial statements and currently anticipates filing on or before the fifth calendar day following the prescribed due date. The notification is signed by Nadav Kidron, President and Chief Executive Officer, on May 15, 2026.
Oramed Pharmaceuticals Inc. reports a Schedule 13G disclosure that Aquamarine Financial (Cayman) Ltd beneficially owns 2,047,652 shares of common stock. The filing shows this represents 5.06% of the class with sole voting and dispositive power over those shares. The form is signed by a director on 05/13/2026.
Oramed Pharmaceuticals Inc. completed the sale of its wholly owned subsidiary Oratech Pharma, Inc. to Lifeward Ltd. and closed a related financing on Lifeward securities. In exchange for Oratech, Oramed received 1,250,363 Lifeward ordinary shares, 1,006,113 pre-funded warrants at an exercise price of $0.0001 per share, and warrants to purchase up to 1,296,296 Lifeward shares at $5.40 per share. Oramed will also receive 4% revenue-sharing payments on Lifeward’s ReWalk Personal Exoskeleton products, subject to a 10-year limit, a maximum aggregate amount, or Lifeward reaching a $200 million market capitalization. Separately, Oramed purchased $9,000,000 in senior secured convertible notes from Lifeward, initially convertible at $5.40 per share, plus additional warrants to buy up to 1,666,666 Lifeward shares at $5.40 per share.
ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a routine tax-related share disposition. On March 30, 2026, 44,818 shares of common stock were used to satisfy tax withholding obligations from the vesting of Restricted Stock Units at $3.31 per share. These shares were not sold in the open market but withheld to cover taxes. Following this, Kidron directly holds 3,422,243 common shares and indirectly holds 126,000 common shares through a wholly-owned corporation.
ORAMED PHARMACEUTICALS INC. Chief Scientific Officer Miriam Kidron reported a tax-related share disposition tied to equity compensation. A total of 435,084 shares of common stock were used to satisfy tax withholding obligations from the vesting and settlement of Restricted Stock Units. These shares were valued at $3.31 per share, based on the closing price immediately before the vesting date. Following this tax-withholding disposition, Kidron directly holds 1,133,138 shares of Oramed common stock.
Oramed Pharmaceuticals Inc. files its annual report outlining a major strategic evolution. The company remains focused on oral delivery of proteins, including an oral insulin capsule, and plans a 60‑patient U.S. clinical trial in 2026 targeting high‑responder diabetes subpopulations via OraTech.
Oramed terminated its joint venture with HTIT, then transferred its POD oral delivery platform and OraTech equity to Lifeward in exchange for up to 49.99% fully diluted equity, warrants and revenue sharing on ReWalk Personal Exoskeleton sales, plus senior secured convertible notes. It also deploys significant capital into healthcare equities, royalties, and loans, including sizable stakes in Alpha Tau, Nano Dimension, Scilex‑linked notes and royalties, a new Corner Ally Ventures fund commitment, and several Israeli real estate and project‑finance loans, while warning that these concentrated investments and counterparties’ performance pose material risks.
ORAMED PHARMACEUTICALS INC. reported that Chief Scientific Officer Miriam Kidron received a grant of 119,558 restricted stock units (RSUs) of common stock. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, providing staged equity-based compensation over two years.
Each RSU represents the right to receive one share of common stock with a par value of $0.012 per share. Following this award, Kidron’s reported direct holdings increased to 1,568,222 shares of common stock, indicating this is a sizable but compensation-related, non-cash acquisition rather than an open-market purchase.
KIDRON NADAV reported acquisition or exercise transactions in this Form 4 filing.
Oramed Pharmaceuticals reported that President and CEO Nadav Kidron received a grant of 167,005 Restricted Stock Units (RSUs) of common stock at no cash cost. The award increases his direct holdings to 3,422,243 shares after the transaction.
The RSUs will vest in eight equal quarterly installments beginning April 1, 2026, aligning a portion of the CEO’s compensation with the company’s long-term performance. Each RSU represents the right to receive one share of Oramed common stock as it vests.
Hexter Joshua reported acquisition or exercise transactions in this Form 4 filing.
ORAMED PHARMACEUTICALS INC. reported that its COO & CBO, Joshua Hexter, received a grant of 95,889 shares of Common Stock in the form of Restricted Stock Units. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, with each RSU delivering one share upon vesting. Following this award, Hexter directly holds a total of 1,160,384 shares of the company’s common stock, reflecting a compensation-related equity grant rather than an open-market purchase.